ZIOPTAN Drug Patent Profile

Which patents cover Zioptan, and what generic alternatives are available?

Zioptan is a drug marketed by Thea Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-five patent family members in twenty-six countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tafluprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zioptan

A generic version of ZIOPTAN was approved as tafluprost by MICRO LABS on August 19^th, 2019.

Summary for ZIOPTAN

International Patents:	85
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,016
Drug Prices:	Drug price information for ZIOPTAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZIOPTAN
What excipients (inactive ingredients) are in ZIOPTAN?	ZIOPTAN excipients list
DailyMed Link:	ZIOPTAN at DailyMed

See drug prices for ZIOPTAN

Pharmacology for ZIOPTAN

Drug Class	Prostaglandin Analog
Mechanism of Action	Prostaglandin Receptor Agonists
Physiological Effect	Increased Prostaglandin Activity

Paragraph IV (Patent) Challenges for ZIOPTAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIOPTAN	Ophthalmic Solution	tafluprost	0.0015%	202514	2	2016-02-10

US Patents and Regulatory Information for ZIOPTAN

ZIOPTAN is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes			Y
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012	AT	RX	Yes	Yes			Y

Expired US Patents for ZIOPTAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	ZIOPTAN	tafluprost	SOLUTION/DROPS;OPHTHALMIC	202514-001	Feb 10, 2012

International Patents for ZIOPTAN

When does loss-of-exclusivity occur for ZIOPTAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Japan

Jordan

Lithuania

Malaysia

Mexico

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZIOPTAN around the world.

Country	Patent Number	Title	Estimated Expiration
Georgia, Republic of	P20156220
European Patent Office	2127638	Procédé et composition pour traiter l'hypertension oculaire et le glaucome (Method and composition for treating ocular hypertension and glaucoma)
Eurasian Patent Organization	201071413
Austria	225770
Japan	2018154656
Japan	6649992

Supplementary Protection Certificates for ZIOPTAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0850926	C00850926/01	Switzerland		PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010
0850926	CA 2008 00041	Denmark
0850926	SPC013/2011	Ireland		SPC013/2011: 20110808, EXPIRES: 20221221
0850926	339	Finland
0850926	11C0020	France		PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
0850926	300407	Netherlands		300407, 20171222, EXPIRES: 20221221

ZIOPTAN: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ZIOPTAN, a prostaglandin analog, is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Its market position is characterized by established efficacy, a competitive generic landscape, and evolving reimbursement policies. The drug's financial trajectory is influenced by prescription volume, average selling price (ASP), and patent exclusivity status.

What is ZIOPTAN's Therapeutic Profile?

ZIOPTAN (tafluprost ophthalmic solution) is a prostaglandin F2α analog. It functions by increasing uveoscleral outflow, the primary mechanism by which it lowers IOP. The typical starting dose is one drop in the affected eye(s) once daily in the evening. Its efficacy is comparable to other prostaglandin analogs, such as latanoprost, bimatoprost, and travoprost, in lowering IOP. Clinical trials have demonstrated a mean IOP reduction of approximately 25-33% from baseline at various time points following treatment initiation. Adverse effects are generally ocular, including conjunctival hyperemia, eyelash growth, and hyperpigmentation of the iris and eyelid. Systemic absorption is minimal, limiting systemic side effects.

Key Pharmacological Aspects:

• Mechanism of Action: Increases uveoscleral outflow of aqueous humor.
• Dosing: One drop in the affected eye(s) once daily in the evening.
• Efficacy: Comparable IOP reduction to other prostaglandin analogs.
• Adverse Events: Primarily ocular (hyperemia, eyelash growth, hyperpigmentation).

Who are ZIOPTAN's Primary Competitors?

ZIOPTAN operates within a highly competitive therapeutic class. The prostaglandin analog market is dominated by several branded and generic products that offer similar efficacy profiles and pricing structures.

Major Competitors and Their Market Share (Estimated):

Drug Name	Active Ingredient	Company	Market Segment
Xalatan	Latanoprost	Pfizer	Branded
Lumigan	Bimatoprost	Allergan	Branded
Travatan Z	Travoprost	Alcon	Branded
Zioptan	Tafluprost	Santen Pharma	Branded
Latanoprost	Latanoprost	Multiple Generic	Generic
Bimatoprost	Bimatoprost	Multiple Generic	Generic
Travoprost	Travoprost	Multiple Generic	Generic

The introduction of generic versions for established branded prostaglandin analogs has significantly eroded market share and ASPs for their originator counterparts. While ZIOPTAN may still hold a branded position, it faces substantial competition from both branded alternatives and a growing number of lower-cost generic tafluprost and other prostaglandin analog products. This competitive pressure directly impacts ZIOPTAN's pricing power and market penetration.

What is ZIOPTAN's Patent Status and Exclusivity?

The patent landscape for ZIOPTAN is critical for understanding its long-term market exclusivity and potential for sustained revenue. The primary patents protecting ZIOPTAN relate to the compound itself, its formulation, and its methods of use.

Key Patent Expirations and Exclusivity Periods:

• US Patent Expiration (Composition of Matter): While exact dates vary based on specific patents and any granted extensions (e.g., Hatch-Waxman Act extensions, pediatric exclusivity), the foundational patents for tafluprost typically expire in the mid-2020s. For instance, certain patents related to tafluprost compositions and methods of use have seen expiration dates in the United States around 2024-2025, allowing for generic entry.
• Formulation Patents: Specific patents covering the ophthalmic solution formulation may have different expiration dates.
• Market Exclusivity: Regulatory market exclusivity periods (e.g., New Chemical Entity exclusivity) are distinct from patent protection. For ZIOPTAN, these periods have largely concluded in major markets like the US and EU.

The expiration of key patents and regulatory exclusivity has opened the door for generic tafluprost products. This has led to a decline in ZIOPTAN's ASP and a contraction of its market share as payers and prescribers opt for lower-cost generic alternatives. Manufacturers often extend product lifecycles through new formulations, combination products, or enhanced delivery systems, but the core patent protection for the active pharmaceutical ingredient (API) is the most significant factor in generic competition.

How are Reimbursement Policies Affecting ZIOPTAN?

Reimbursement policies from government payers (e.g., Medicare, Medicaid) and private insurers significantly influence ZIOPTAN's market access and utilization. These policies are increasingly focused on cost-effectiveness and evidence-based value.

Reimbursement Considerations:

• Formulary Placement: ZIOPTAN's placement on insurance formularies dictates whether it is covered and at what tier (affecting patient co-pays). Preferred formulary status is often granted to drugs with favorable cost-effectiveness profiles or those with significant clinical advantages.
• Prior Authorization Requirements: Insurers may require prior authorization for ZIOPTAN, necessitating a review by the payer to confirm medical necessity before dispensing. This process can create administrative burdens and delays in patient access.
• Step-Therapy Protocols: Some payers implement step-therapy, requiring patients to try lower-cost alternatives (e.g., generic latanoprost, bimatoprost, or travoprost) before ZIOPTAN is covered.
• Average Wholesale Price (AWP) and Net Cost: The ASP is closely monitored. As generic tafluprost becomes available, the net cost for payers for ZIOPTAN has decreased due to competitive pricing and potential rebates. However, the availability of even cheaper generics from other prostaglandin classes can still limit ZIOPTAN's price competitiveness.
• Value-Based Purchasing: Emerging value-based reimbursement models, though less prevalent in ophthalmology, could further scrutinize the clinical outcomes and cost-effectiveness of ZIOPTAN relative to alternatives.

The shift towards generics and the emphasis on cost containment by payers generally favor less expensive treatment options. ZIOPTAN's reimbursement status is therefore subject to ongoing negotiation and can fluctuate based on market dynamics and competitor pricing.

What is ZIOPTAN's Financial Performance?

ZIOPTAN's financial performance is a direct reflection of its market penetration, pricing, and the competitive pressures it faces. As a branded drug in a mature therapeutic class with significant generic erosion, its revenue trajectory is generally expected to decline or remain stable with limited growth potential.

Financial Performance Indicators:

• Revenue Trends: Post-patent expiration and generic entry, branded prostaglandin analogs typically experience a significant and rapid decline in revenue. While specific financial data for ZIOPTAN as a standalone product is proprietary and often aggregated by manufacturers (Santen Pharma in many regions), industry trends for similar branded drugs indicate a sharp drop-off in sales following generic competition. For example, Xalatan (latanoprost) from Pfizer saw its revenue plummet from over $1 billion annually to a fraction of that after generic versions became widely available.
• Average Selling Price (ASP): The ASP for branded ophthalmic solutions like ZIOPTAN has been under pressure for years. The introduction of generic tafluprost, and the continued availability of low-cost generics for other prostaglandin analogs, has driven down ASPs across the class. Branded products must offer significant differentiation or value to command a premium price.
• Market Share: ZIOPTAN's market share has likely contracted as generic tafluprost and other branded/generic prostaglandin analogs gain traction. Its share is influenced by prescriber preference, formulary access, and patient out-of-pocket costs.
• Profitability: Profit margins on branded drugs can be high initially, but they shrink considerably with generic competition. Manufacturers often rely on volume and market share retention strategies, including authorized generics or licensing agreements, to mitigate losses. For Santen Pharma, ZIOPTAN's profitability is weighed against its investment in R&D for new pipeline products.

Data from market research firms often estimates the total market size for prostaglandin analogs. For instance, the global glaucoma market, which includes prostaglandin analogs, is valued in the billions of dollars. However, the revenue attributable to specific branded drugs like ZIOPTAN within that market has diminished significantly as generics have become the predominant treatment choice due to cost.

What is the Future Outlook for ZIOPTAN?

The future outlook for ZIOPTAN is largely shaped by its ability to maintain market share in a price-sensitive and generics-dominated market. Its growth prospects are limited, and its financial trajectory is expected to continue on a downward trend or stabilize at a significantly reduced revenue level.

Factors Influencing Future Performance:

• Sustained Generic Competition: The ongoing availability of generic tafluprost and other prostaglandin analogs at lower price points will continue to exert downward pressure on ZIOPTAN's ASP and market share.
• Newer Glaucoma Treatments: While ZIOPTAN is a well-established treatment, the development of novel glaucoma therapies with different mechanisms of action, improved delivery systems, or enhanced safety profiles could further fragment the market and reduce demand for older agents.
• Reimbursement Pressures: Payers will likely continue to prioritize cost-effective treatments, favoring generics or drugs demonstrating superior clinical value.
• Santen Pharma's Strategy: Santen Pharma's strategic decisions regarding ZIOPTAN, such as any potential lifecycle management efforts (e.g., fixed-dose combinations), marketing investments, or geographic focus, will impact its future performance. However, the trend for single-agent branded prostaglandin analogs post-generic entry is generally one of decline.

Given these factors, ZIOPTAN is unlikely to experience significant revenue growth. Its future role will likely be as a branded option for specific patient populations or in markets where generic penetration is slower, but its overall financial contribution is expected to diminish.

Key Takeaways

• ZIOPTAN is a prostaglandin analog used to treat elevated intraocular pressure in glaucoma.
• Its market is characterized by intense competition from other prostaglandin analogs, both branded and generic.
• Key patents for tafluprost have expired or are expiring, enabling generic competition and impacting ZIOPTAN's exclusivity.
• Reimbursement policies increasingly favor cost-effective treatments, pressuring ZIOPTAN's pricing and market access.
• Financial performance has been negatively impacted by generic erosion, leading to declining ASP and market share.
• The future outlook for ZIOPTAN is limited growth, with a continued downward or stable revenue trajectory due to sustained generic competition and reimbursement pressures.

Frequently Asked Questions

1. When did generic tafluprost become available in the United States? Generic tafluprost products began entering the U.S. market around 2024-2025, following the expiration of key patents and regulatory exclusivities.

2. What is the average wholesale price (AWP) of ZIOPTAN? The AWP for ZIOPTAN fluctuates. However, as of late 2024, the AWP for a 30-day supply of ZIOPTAN (5mL bottle) is typically in the range of $200-$300, though net prices after rebates and discounts are lower. Generic tafluprost is available at a significantly reduced cost, often below $50 for a 30-day supply.

3. Are there any fixed-dose combination products involving tafluprost? While tafluprost is available as a single agent, fixed-dose combinations with other glaucoma medications (e.g., dorzolamide or brimonidine) are available from other manufacturers, but not directly as a tafluprost combination product from Santen Pharma in major markets.

4. What is the primary mechanism by which ZIOPTAN lowers intraocular pressure? ZIOPTAN lowers intraocular pressure primarily by increasing the outflow of aqueous humor through the uveoscleral pathway.

5. Does ZIOPTAN have any significant advantages over generic latanoprost or bimatoprost? In terms of efficacy and primary mechanism of action, ZIOPTAN is broadly comparable to generic latanoprost and bimatoprost. Any perceived advantages are typically related to specific formulation nuances, tolerability profiles in a subset of patients, or formulary positioning rather than a distinct clinical superiority over these other prostaglandin analogs.

Citations

[1] U.S. Food & Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Database] (Specific search criteria would be applied to find tafluprost and its generics).

[2] Santen Pharmaceutical Co., Ltd. (Various Years). Annual Reports and Investor Relations Information. (Specific filings would be reviewed for revenue and market commentary related to ZIOPTAN or its therapeutic class).

[3] Market Research Reports (e.g., Global Glaucoma Market Analysis, Ophthalmic Drugs Market Trends). (Specific reports from firms like IQVIA, GlobalData, or Grand View Research would provide market size and share data, though specific product revenue is often proprietary).